Blincyto (Blinatumomab)
blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL vial], 1 pack · INJECTION · PBS code 11117D
AUTHORITY_REQUIREDWhat it costs
AU$2759.53 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2017-05-01.
- • Repeats: 2.
- • PBS program: IP.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Acute lymphoblastic leukaemia
Consolidation treatment of relapsed or refractory B-precursor cell ALL
Patient must have previously received PBS-subsidised induction treatment with this drug for relapsed or refractory B-precursor cell ALL; AND
Patient must have achieved a complete remission; or
Patient must have achieved a complete remission with partial haematological recovery; AND
The treatment must not be more than 3 treatment cycles under this restriction in a lifetime; AND
Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug.
Sponsor: Amgen Australia Pty Limited ABN 31 051 057 428
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.